CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Cipro In Sodium Chloride 0.9% In Plastic Container, and what generic alternatives are available?

Cipro In Sodium Chloride 0.9% In Plastic Container is a drug marketed by Bayer Pharms and is included in one NDA.

The generic ingredient in CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is ciprofloxacin. There are thirty-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cipro In Sodium Chloride 0.9% In Plastic Container

A generic version of CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER was approved as ciprofloxacin by HIKMA FARMACEUTICA on December 22^nd, 2009.

Summary for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019858-001	Dec 26, 1990		DISCN	No	No

International Patents for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

See the table below for patents covering CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	8607021
Finland	843587
Spain	535832

Supplementary Protection Certificates for CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003

Cipro in Sodium Chloride 0.9% in Plastic Container: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

This analysis examines the investment potential for Ciprofloxacin (Cipro) in Sodium Chloride 0.9% in plastic containers, emphasizing market trends, competitive landscape, regulatory environment, and financial prospects. As an established antibiotic, Cipro faces evolving market dynamics driven by antibiotic stewardship policies, generic erosion, and emerging resistance. Understanding these factors is essential for stakeholders assessing long-term viability and profitability.

---

Product Overview

Attribute	Details
Active Ingredient	Ciprofloxacin Hydrochloride
Formulation	0.9% Sodium Chloride in Plastic (IV infusion)
Approved Use	Bacterial infections, including urinary tract infections, respiratory infections, and skin infections
Packaging	Plastic containers (primarily 100 mL, 250 mL, 500 mL)
Route of Administration	Intravenous (IV)

Note: The product is typically marketed as a hospital IV infusion, requiring regulatory approval per regional agencies (e.g., FDA, EMA).

---

Market Dynamics

1. Global Market Size and Forecast

Year	Market Value (USD Billions)	Compound Annual Growth Rate (CAGR)	Notes
2022	$1.1	-	Base estimate
2027	$1.4	5.2%	Projected growth, driven by increasing bacterial infections, aging populations

Sources: Grand View Research, 2022; Statista, 2023

2. Key Market Drivers

• Incidence of Bacterial Infections: Increasing prevalence of multidrug-resistant bacteria increases reliance on IV antibiotics like Cipro.
• Hospitalization Trends: Rising inpatient care requirements expand IV therapy utilization.
• Aging Population: Greater susceptibility to infections in the elderly supports sustained demand.

Factor	Impact	Trend
Antibiotic Use	Continued essential use	Stable but declining due to stewardship
Resistance Patterns	Shifts prescribing habits	Raises demand for newer or alternative antibiotics
Regulatory Policies	Benchmarking against stewardship	Moderate restrictions

3. Market Constraints

Constraint	Effect
Antibiotic Stewardship	Limits overuse, promotes restraint
Generic Competition	Erosion of branded margins
Resistance Concerns	Potential for reduced efficacy
Regulatory Barriers	Import/export restrictions

4. Competitive Landscape

Competitors	Product Type	Market Share	Notes
Bayer	Original Cipro	60-70%	Patented formulations phased out in many markets
Mylan, Teva	Generics	20-25%	Price competition increased
Other Generics and Biosimilars	Various	5-15%	Growing presence

Note: Patent expirations (e.g., US patent expired in 2014) catalyzed generics proliferation.

---

Financial Trajectory

1. Revenue Drivers

• Unit Sales Volume: Directly correlates with hospital demand and infection rates.
• Pricing Strategies: Premium for branded vs. competitive for generics.
• Market Penetration: Geographic expansion and hospital procurement contracts.

2. Profitability Index

Parameter	2023 Estimate	Notes
Wholesale Price per Container	USD $15-25	Varies by region and brand origin
Cost of Goods Sold (COGS)	USD $4-8	Manufacturing and raw materials
Gross Margin	60-70%	Declining trend due to generic competition
R&D and Regulatory	USD $2-3 million/year	Ongoing for new formulations or indications

3. CAGR Projections (2023-2028)

Scenario	CAGR	Comment
Conservative	3-4%	Market saturation, intense price competition
Optimistic	5-7%	Increased infection rates, hospital expansions

Note: Margins are increasingly squeezed by competition, but volume growth can offset.

4. Investment Milestones & Risks

Milestone	Timeline	Associated Risks
Regulatory Approval for New Indications	1-2 years	Regulatory delays or denials
Market Expansion (Emerging Markets)	2-3 years	Local regulatory barriers, intellectual property issues
Patent Challenge or Litigation	Varies	Patent expiry and generic entry

---

Regulatory and Policy Environment

Region	Regulatory Body	Key Policies	Impact on Market
US	FDA	Strict quality standards; antibiotic stewardship policies	Moderate growth, focus on minimizing resistance
EU	EMA	Similar standards with emphasis on biosimilars	Stable demand, potential for biosimilar uptake
Asia-Pacific	Local authorities	Growing investment in healthcare infrastructure	Emerging market opportunities

Comparative Analysis: Original vs. Generic

Aspect	Original Cipro (Bayer)	Generics	Implication
Price	Higher	Lower	Cost pressures target generics
Market Share	Dominant (pre-patent expiry)	Growing	Shifting landscape post-patent
Quality Standards	Highest	Similar	Regulatory compliance vital

---

Strategic Considerations for Investors

• Patent Status & Lifecycle Management: With patent expiry, focus on generic competition and potential for premium branding.
• Formulation Differentiation: Investigate opportunities for delivering superior stability, bioavailability, or combination therapies.
• Market Penetration in Emerging Regions: Capitalize on expanding healthcare infrastructure and unmet needs.
• Regulatory and Reimbursement Trends: Monitor policies that could influence drug accessibility and profitability.

---

Conclusion

Investing in Ciprofloxacin in Sodium Chloride 0.9% in plastic containers presents moderate growth prospects, driven primarily by hospital demand for IV antibiotics amid increasing bacterial infections. However, significant generic competition, stewardship policies, and resistance trends pose challenges. A diversified strategy, emphasizing market expansion, formulation innovation, and regulatory navigation, can enhance long-term financial viability.

---

Key Takeaways

• The global IV antibiotic market is projected to grow at 5.2% CAGR through 2027, but Ciprofloxacin faces pressure from generics and resistance.
• Hospital demand sustains near-term revenue, but margins diminish due to price competition.
• Emerging markets offer growth opportunities, contingent on regulatory and reimbursement environments.
• Continuous R&D and formulation enhancements can mitigate generic erosion.
• Regulatory compliance and stewardship policies critically influence market access and profitability.

---

FAQs

1. How does patent expiration affect the profitability of Cipro in sodium chloride IV?
Patent expiry typically leads to increased generic competition, reducing prices and margins. Companies must leverage brand recognition, quality, or formulation differentiation to maintain profitability.

2. What are the primary risks associated with investing in this product?
Key risks include rising resistance diminishing efficacy, stringent antibiotic stewardship policies limiting use, and intense competition from generics leading to price erosion.

3. Are there opportunities for formulation innovation?
Yes. Developing formulations with improved stability, reduced infusion times, or combination therapies can create competitive advantages and extend product lifecycle.

4. How significant is the role of emerging markets in the future of Cipro IV?
Growing healthcare infrastructure and infection rates in regions like Asia-Pacific and Latin America present substantial growth opportunities if regulatory hurdles are appropriately managed.

5. What regulatory factors could influence market dynamics?
Stringent approval standards, approval of biosimilars, and reimbursement policies can impact market share, pricing, and overall profitability.

---

References

[1] Grand View Research, "Antibiotics Market Size, Share & Trends Analysis," 2022.
[2] Statista, "Global market for intravenous antibiotics," 2023.
[3] US Food and Drug Administration (FDA), "Generic Drug Approval Packages," 2022.
[4] European Medicines Agency (EMA), "Guidelines on antimicrobial resistance," 2022.